FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 354:329-331 January 26, 2006 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mangano, D. T. PubMed Citation

It is a cornerstone of medical practice to "first, do no harm." Yet the body of evidence that is sufficient to demonstrate efficacy for a new drug is rarely large enough to provide absolute assurance that harmful side effects do not exist. Thus, ongoing surveillance is necessary to detect adverse events.

There are many reasons why the randomized trials that are adequate for demonstrating drug efficacy may not be adequate for the recognition of important side effects (see table). Randomized trials may be too small to permit the detection of adverse events. For instance, for a continuous outcome such . . . [Full Text of this Article]

Source Information

Dr. Hunter is a professor of epidemiology at the Harvard School of Public Health, Boston, and a statistical consultant to the Journal.

Related Letters:

Aprotinin in Cardiac Surgery
Ferraris V. A., Bridges C. R., Anderson R. P., for the Blood Conservation Guideline , Brown J. R., Birkmeyer N. J.O., O'Connor G. T., Levy J. H., Ramsay J. G., Guyton R. A., D'Ambra M. N., Mangano D. T.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1953-1957, May 4, 2006. Correspondence

This article has been cited by other articles:

• Furnary, A. P., Wu, Y., Hiratzka, L. F., Grunkemeier, G. L., Page, U. S. 3rd (2007). Aprotinin Does Not Increase the Risk of Renal Failure in Cardiac Surgery Patients. Circulation 116: I-127-I-133 [Abstract] [Full Text]  
• Brunkhorst, F. M., Schortgen, F., Sakr, Y., Vincent, J. L. (2007). Effects of hydroxyethyl starch in critically ill patients. Br J Anaesth 98: 842-844 [Full Text]  
• The Society of Thoracic Surgeons Blood Conservatio, , Ferraris, V. A., Ferraris, S. P., Saha, S. P., Hessel, E. A. II, Haan, C. K., Royston, B. D., Bridges, C. R., Higgins, R. S.D., Despotis, G., Brown, J. R., The Society of Cardiovascular Anesthesiologists Sp, , Spiess, B. D., Shore-Lesserson, L., Stafford-Smith, M., Mazer, C. D., Bennett-Guerrero, E., Hill, S. E., Body, S. (2007). Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline. Ann. Thorac. Surg. 83: S27-S86 [Abstract] [Full Text]  
• Mangano, D. T., Miao, Y., Vuylsteke, A., Tudor, I. C., Juneja, R., Filipescu, D., Hoeft, A., Fontes, M. L., Hillel, Z., Ott, E., Titov, T., Dietzel, C., Levin, J., for the Investigators of The Multicenter Study of, (2007). Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery. JAMA 297: 471-479 [Abstract] [Full Text]  
• Ferguson, T. B. Jr (2007). Aprotinin--Are There Lessons Learned?. JAMA 297: 527-529 [Full Text]  
• Mangano, D. T., Rieves, R. D., Weiss, K. D. (2006). Judging the safety of aprotinin.. NEJM 355: 2261-2262 [Full Text]  
• Dietrich, W., Busley, R., Kriner, M. (2006). High-Dose Aprotinin in Cardiac Surgery: Is High-Dose High Enough?: An Analysis of 8281 Cardiac Surgical Patients Treated with Aprotinin. Anesth. Analg. 103: 1074-1081 [Abstract] [Full Text]  
• Ferraris, V. A., Bridges, C. R., Anderson, R. P., for the Blood Conservation Guideline, , Brown, J. R., Birkmeyer, N. J.O., O'Connor, G. T., Levy, J. H., Ramsay, J. G., Guyton, R. A., D'Ambra, M. N., Mangano, D. T. (2006). Aprotinin in cardiac surgery.. NEJM 354: 1953-1957 [Full Text]  
• (2006). Severe Hepatotoxicity with Telithromycin. JWatch Infect. Diseases 2006: 1-1 [Full Text]